Objective To investigate the clinical significance of atypical squamous cells(ASC) in cervical sm... more Objective To investigate the clinical significance of atypical squamous cells(ASC) in cervical smear,its management strategies and the value of human papillomavirus (HPV) test.Methods Colposcopy,convertional Pap smear and HPV test were performed in 126 women with a ...
Objective: To assess the effect of TruScreen™ (an objective optoelectronic cervical screening dev... more Objective: To assess the effect of TruScreen™ (an objective optoelectronic cervical screening device) in improving the sensitivity of cervical screening programs either alone or in combination with Papanicolaou (PAP) smear or human papilloma virus (HPV) DNA screening. Material and Methods: Our study was performed in 285 patients with abnormal Pap test results. TruScreen™ and HPV screening methods were performed in all participants. Consistency and differences between the tests were compared with cervical biopsy results. Results: TruScreen™ was found to be an approach method in the determination of cervical pathologies (ROC curve area underlined=0.606) and with an 89.5% negative predictive value. HPV screening remains a counterpart to TruScreen™ with a 0.620 area underlined in the ROC curve and an 83% negative predictive value. Conclusion: As determined in our study, TruScreen™ with a sensitivity of 86.1% can be used as a screening test with instant and not professional dependent results for cervical cancer screening. Avoiding from subjectivity in interpretation of Pap smears and requirement for pathologists, Tru- Screen™ can be a used for cervical cancer screening especially in countries with a low socio-economic status. The combination of TruScreen™ and HPV screening was not able to demonstrate a significant rise of effectiveness in screening.
Background: Uterine papillary serous tumors are rarely seen and behave aggressively. Our aim was ... more Background: Uterine papillary serous tumors are rarely seen and behave aggressively. Our aim was to evaluate uterine papillary serous tumors arising from polyps. Materials and Methods: Clinicopathological data of patients with uterine serous cancer arising from a polyp at the Gynecological Oncology Department of Zekai Tahir Burak Women’s Health Education and Research Hospital were reviewed retrospectively. Results: We analyzed patients according to FIGO 2009 staging system as stage 1A and higher than stage 1A (3 and 6, respectively). All the patients were postmenopausal. Mean CA-125, CA-19.9 and CA15.3 levels were elevated in higher than stage 1A group. However we did not find a statistical difference between age, parity, polyp size, CA-125, CA-15.3, CA-19.9 and CEA levels. Lympho-vascular space invasion (LVSI) showed predictivity for advanced disease (p=0.025). Conclusions: The histopathologic nature of uterine serous carcinoma is a unique entity. LVSI is a prognosticator for defining an advanced stage uterine papillary tumor
Objective To investigate the clinical significance of atypical squamous cells(ASC) in cervical sm... more Objective To investigate the clinical significance of atypical squamous cells(ASC) in cervical smear,its management strategies and the value of human papillomavirus (HPV) test.Methods Colposcopy,convertional Pap smear and HPV test were performed in 126 women with a ...
Objective: To assess the effect of TruScreen™ (an objective optoelectronic cervical screening dev... more Objective: To assess the effect of TruScreen™ (an objective optoelectronic cervical screening device) in improving the sensitivity of cervical screening programs either alone or in combination with Papanicolaou (PAP) smear or human papilloma virus (HPV) DNA screening. Material and Methods: Our study was performed in 285 patients with abnormal Pap test results. TruScreen™ and HPV screening methods were performed in all participants. Consistency and differences between the tests were compared with cervical biopsy results. Results: TruScreen™ was found to be an approach method in the determination of cervical pathologies (ROC curve area underlined=0.606) and with an 89.5% negative predictive value. HPV screening remains a counterpart to TruScreen™ with a 0.620 area underlined in the ROC curve and an 83% negative predictive value. Conclusion: As determined in our study, TruScreen™ with a sensitivity of 86.1% can be used as a screening test with instant and not professional dependent results for cervical cancer screening. Avoiding from subjectivity in interpretation of Pap smears and requirement for pathologists, Tru- Screen™ can be a used for cervical cancer screening especially in countries with a low socio-economic status. The combination of TruScreen™ and HPV screening was not able to demonstrate a significant rise of effectiveness in screening.
Background: Uterine papillary serous tumors are rarely seen and behave aggressively. Our aim was ... more Background: Uterine papillary serous tumors are rarely seen and behave aggressively. Our aim was to evaluate uterine papillary serous tumors arising from polyps. Materials and Methods: Clinicopathological data of patients with uterine serous cancer arising from a polyp at the Gynecological Oncology Department of Zekai Tahir Burak Women’s Health Education and Research Hospital were reviewed retrospectively. Results: We analyzed patients according to FIGO 2009 staging system as stage 1A and higher than stage 1A (3 and 6, respectively). All the patients were postmenopausal. Mean CA-125, CA-19.9 and CA15.3 levels were elevated in higher than stage 1A group. However we did not find a statistical difference between age, parity, polyp size, CA-125, CA-15.3, CA-19.9 and CEA levels. Lympho-vascular space invasion (LVSI) showed predictivity for advanced disease (p=0.025). Conclusions: The histopathologic nature of uterine serous carcinoma is a unique entity. LVSI is a prognosticator for defining an advanced stage uterine papillary tumor
Uploads
Papers by Emre Ozgu
screening programs either alone or in combination with Papanicolaou (PAP) smear or human papilloma virus (HPV) DNA screening.
Material and Methods: Our study was performed in 285 patients with abnormal Pap test results. TruScreen™ and HPV screening methods
were performed in all participants. Consistency and differences between the tests were compared with cervical biopsy results.
Results: TruScreen™ was found to be an approach method in the determination of cervical pathologies (ROC curve area underlined=0.606)
and with an 89.5% negative predictive value. HPV screening remains a counterpart to TruScreen™ with a 0.620 area underlined in the ROC curve
and an 83% negative predictive value.
Conclusion: As determined in our study, TruScreen™ with a sensitivity of 86.1% can be used as a screening test with instant and not professional
dependent results for cervical cancer screening. Avoiding from subjectivity in interpretation of Pap smears and requirement for pathologists, Tru-
Screen™ can be a used for cervical cancer screening especially in countries with a low socio-economic status. The combination of TruScreen™
and HPV screening was not able to demonstrate a significant rise of effectiveness in screening.
evaluate uterine papillary serous tumors arising from polyps. Materials and Methods: Clinicopathological
data of patients with uterine serous cancer arising from a polyp at the Gynecological Oncology Department of
Zekai Tahir Burak Women’s Health Education and Research Hospital were reviewed retrospectively. Results:
We analyzed patients according to FIGO 2009 staging system as stage 1A and higher than stage 1A (3 and 6,
respectively). All the patients were postmenopausal. Mean CA-125, CA-19.9 and CA15.3 levels were elevated
in higher than stage 1A group. However we did not find a statistical difference between age, parity, polyp size,
CA-125, CA-15.3, CA-19.9 and CEA levels. Lympho-vascular space invasion (LVSI) showed predictivity for
advanced disease (p=0.025). Conclusions: The histopathologic nature of uterine serous carcinoma is a unique
entity. LVSI is a prognosticator for defining an advanced stage uterine papillary tumor
screening programs either alone or in combination with Papanicolaou (PAP) smear or human papilloma virus (HPV) DNA screening.
Material and Methods: Our study was performed in 285 patients with abnormal Pap test results. TruScreen™ and HPV screening methods
were performed in all participants. Consistency and differences between the tests were compared with cervical biopsy results.
Results: TruScreen™ was found to be an approach method in the determination of cervical pathologies (ROC curve area underlined=0.606)
and with an 89.5% negative predictive value. HPV screening remains a counterpart to TruScreen™ with a 0.620 area underlined in the ROC curve
and an 83% negative predictive value.
Conclusion: As determined in our study, TruScreen™ with a sensitivity of 86.1% can be used as a screening test with instant and not professional
dependent results for cervical cancer screening. Avoiding from subjectivity in interpretation of Pap smears and requirement for pathologists, Tru-
Screen™ can be a used for cervical cancer screening especially in countries with a low socio-economic status. The combination of TruScreen™
and HPV screening was not able to demonstrate a significant rise of effectiveness in screening.
evaluate uterine papillary serous tumors arising from polyps. Materials and Methods: Clinicopathological
data of patients with uterine serous cancer arising from a polyp at the Gynecological Oncology Department of
Zekai Tahir Burak Women’s Health Education and Research Hospital were reviewed retrospectively. Results:
We analyzed patients according to FIGO 2009 staging system as stage 1A and higher than stage 1A (3 and 6,
respectively). All the patients were postmenopausal. Mean CA-125, CA-19.9 and CA15.3 levels were elevated
in higher than stage 1A group. However we did not find a statistical difference between age, parity, polyp size,
CA-125, CA-15.3, CA-19.9 and CEA levels. Lympho-vascular space invasion (LVSI) showed predictivity for
advanced disease (p=0.025). Conclusions: The histopathologic nature of uterine serous carcinoma is a unique
entity. LVSI is a prognosticator for defining an advanced stage uterine papillary tumor